Literature DB >> 18520037

BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells.

Chun Sung Kim1, Seon-Ho Cho, Hong Sung Chun, Sook-Young Lee, Hitoshi Endou, Yoshikatsu Kanai, Do Kyung Kim.   

Abstract

PURPOSE: L-Type amino acid transporter 1 (LAT1) is highly expressed in cancer cells to support their continuous growth and proliferation. We have examined the effect of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), an inhibitor of system L amino acid transporters, and the mechanism by which BCH suppresses cell growth in cancer cells.
METHODS: The effect of BCH and the mechanism of BCH on cell growth suppression in cancer cells were examined using amino acid transport measurement, MTT assay, DNA fragmentation analysis, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and immunoblotting.
RESULTS: BCH inhibited L-leucine transport in a concentration-dependent manner, and it inhibited cell growth in a time-dependent manner in KB human oral epidermoid carcinoma cells, Saos2 human osteogenic sarcoma cells and C6 rat glioma cells. The formation of a DNA ladder was observed, and the number of TUNEL-positive cells was increased with BCH treatment. Furthermore, the proteolytic processing of caspase-3 in KB and C6 cells and of caspase-7 in KB, Saos2 and C6 cells was increased by BCH treatment.
CONCLUSION: These results suggest that the inhibition of LAT1 activity by BCH leads to apoptotic cancer cell death by inducing intracellular depletion of neutral amino acids necessary for cancer cell growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18520037     DOI: 10.1248/bpb.31.1096

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  47 in total

1.  Inhibition of Large Neutral Amino Acid Transporters Suppresses Kynurenic Acid Production Via Inhibition of Kynurenine Uptake in Rodent Brain.

Authors:  Airi Sekine; Yusuke Kuroki; Tomomi Urata; Noriyuki Mori; Tsutomu Fukuwatari
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

2.  Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.

Authors:  Aiko Nobusawa; Mai Kim; Kyoichi Kaira; Go Miyashita; Akihide Negishi; Noboru Oriuchi; Tetsuya Higuchi; Yoshito Tsushima; Yoshikatsu Kanai; Satoshi Yokoo; Tetsunari Oyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-26       Impact factor: 9.236

3.  Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.

Authors:  Deanna N Edwards; Verra M Ngwa; Ariel L Raybuck; Shan Wang; Yoonha Hwang; Laura C Kim; Sung Hoon Cho; Yeeun Paik; Qingfei Wang; Siyuan Zhang; H Charles Manning; Jeffrey C Rathmell; Rebecca S Cook; Mark R Boothby; Jin Chen
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

Review 4.  L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.

Authors:  Qian Wang; Jeff Holst
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

5.  In vivo and in vitro evaluations of intestinal gabapentin absorption: effect of dose and inhibitors on carrier-mediated transport.

Authors:  Malte Selch Larsen; Sidsel Frølund; Martha Kampp Nøhr; Carsten Uhd Nielsen; Mats Garmer; Mads Kreilgaard; René Holm
Journal:  Pharm Res       Date:  2014-09-03       Impact factor: 4.200

6.  Preclinical evaluation of an 18F-trifluoroborate methionine derivative for glioma imaging.

Authors:  Xiangyu Yang; Zhibo Liu; Huimin Zhang; Zhu Li; Jeeva P Munasinghe; Gang Niu; Gaojun Teng; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-29       Impact factor: 9.236

7.  Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer.

Authors:  Kyoichi Kaira; Noboru Oriuchi; Hisao Imai; Kimihiro Shimizu; Noriko Yanagitani; Noriaki Sunaga; Takeshi Hisada; Osamu Kawashima; Yosuke Kamide; Tamotsu Ishizuka; Yoshikatsu Kanai; Takashi Nakajima; Masatomo Mori
Journal:  Exp Ther Med       Date:  2010-07-20       Impact factor: 2.447

8.  Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts.

Authors:  F I Tade; W G Wiles; G Lu; B Bilir; O Akin-Akintayo; J S Lee; D Patil; W Yu; C Ormenisan Gherasim; B Fei; C S Moreno; A O Osunkoya; E J Teoh; S Oka; H Okudaira; M M Goodman; D M Schuster
Journal:  Amino Acids       Date:  2018-06-15       Impact factor: 3.520

9.  LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.

Authors:  Arik A Zur; Huan-Chieh Chien; Evan Augustyn; Andrew Flint; Nathan Heeren; Karissa Finke; Christopher Hernandez; Logan Hansen; Sydney Miller; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2016-09-03       Impact factor: 2.823

10.  High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.

Authors:  M Kikuchi; T Mikami; T Sato; W Tokuyama; K Araki; M Watanabe; K Saigenji; I Okayasu
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.